A clinical-stage biotech building targeted pills for RAS-driven cancers, a mutation family behind many hard-to-treat tumors. Think of it as designing precision locksmiths for a notoriously tricky cancer switch.
No product revenue yet; the business burns cash, with net losses of USD 1.13B in 2025 and USD 0.60B in 2024. Money comes from partnerships like the Sanofi SHP2 deal, not from selling drugs.
Its RAS-targeting platform is highly specialized, but competitors like Amgen and Mirati Therapeutics are also chasing KRAS mutations, and clinical failure could erase any edge. The moat is unproven until drugs clear trials.
Sell (sector percentile 27) — value D-, growth F, profitability D-, momentum A, revisions B+. Updated daily, sector-relative, identical for every user.
Key events, in time order
Truist raises PT to $231 from $210, citing newly incorporated opportunities for elironrasib and zoldonrasib
Earnings reflect continued investment in late-stage programs and commercial prep; analysts expect darax approval by late Aug or early Sept
Accelerated review brings first commercial product closer
CEO acknowledges interest from many companies but says sale not a priority, per FT
None yet
None yet
The user is tracking changes in their portfolio, noting a decrease in $ABVX and closing positions in $IVAQ and $LQDA. The discussion is about portfolio management and recent trading activity.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
